In an attempt to expand the scope of its immuno-oncology franchise, Bristol-Myers Squibb (BMS) is to leverage French start-up Enterome Bioscience’s metagenomics platform in a collaboration that aims to develop companion diagnostics and microbiome-related therapeutics for the treatment of cancer. The two companies will also seek to identify microbiome-derived biomarkers to improve clinical outcomes for patients treated with BMS’ immuno-oncology assets. BMS is the first major pharmaceutical company to sign a microbiome deal in the immuno-oncology field.